STAAR Surgical Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This STAAR Surgical Value Chain Analysis gives a clear, company-specific view of how STAAR Surgical creates value across support and primary activities. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
STAAR Surgical Company's firm infrastructure is built to support a tightly controlled medical-device model, with global quality, regulatory, finance, and legal systems tied to product approval, traceability, and disciplined execution across international markets. In FY2025, this mattered more because the business still had to manage highly regulated ICL sales across dozens of countries while protecting compliance at every step. Its infrastructure is a core enabler, not overhead.
Human Resource Management
STAAR Surgical relies on specialized talent in R&D, quality assurance, manufacturing, and surgeon support. In FY2025, that skill mix mattered because ophthalmic-device work needs cleanroom discipline, tight process control, and credible field teams; hiring people with device and sterile-manufacturing experience helps keep output consistent and surgeon confidence high.
Technology Development
STAAR Surgical Company keeps investing in Visian ICL lens design and delivery systems, which helps improve surgical handling and clinical outcomes. The EVO ICL platform can treat myopia up to -20.0 D, hyperopia up to +10.0 D, and astigmatism up to 4.0 D, so the addressable pool is broad. In 2025, this tech focus supports stronger differentiation in refractive surgery.
Procurement
STAAR Surgical Company's procurement must lock down medical-grade inputs, precision parts, packaging, and sterilization services under tight supplier controls. In FY2025, this matters because even small supplier slips can hit implant quality, raise defect risk, and disrupt supply for lenses and related components. Strong sourcing also helps STAAR Surgical Company hold costs down while keeping continuity in a regulated, low-tolerance supply chain.
STAAR Surgical Company's FY2025 Backbone: Quality, Compliance, and Precision
STAAR Surgical Company's support activities in FY2025 centered on quality, regulatory, and global systems that keep EVO ICL approvals, traceability, and compliance tight across markets. Its people base, R&D, and field support stayed focused on sterile-device execution and surgeon training. Procurement stayed strict on medical-grade inputs, precision parts, and sterilization to protect yield and continuity.
| Support activity | FY2025 focus |
|---|---|
| Infrastructure | Global quality and regulatory control |
| Human resources | Device, QA, and cleanroom talent |
| Technology | EVO ICL design and delivery systems |
| Procurement | Medical-grade inputs and sterilization |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
STAAR Surgical Company's inbound logistics centers on qualified suppliers for raw materials, packaging, and manufacturing inputs, with tight incoming checks that support traceability and cut contamination risk for implantable lenses.
That control matters in a high-spec medtech chain: in fiscal 2025, STAAR Surgical had to protect product quality while serving a global ICL franchise that depends on clean, documented material flow.
Careful supplier vetting and lot-level tracking help reduce scrap, delays, and recall exposure.
Operations
STAAR Surgical Company's Operations rely on precision lens manufacturing, inspection, sterilization, and final release testing. In FY2025, every yield point matters because a few basis points of scrap or rework can move gross margin fast. Sterility and repeatability also shape surgeon confidence, especially for implantable lenses.
With a high-spec device flow, tight process control lowers batch failures and speeds release. That keeps product consistent, supports traceability, and protects the quality signal in each shipment.
Outbound Logistics
STAAR Surgical Company moves finished lenses and delivery systems through controlled warehousing and global distributors, with products sold in over 75 countries in fiscal 2025. This outbound step matters because surgeons need the right lens model, power, and delivery system on time, with no shipment errors.
In fiscal 2025, STAAR Surgical reported net sales of about $271.9 million, so even small stock or shipping delays can hit revenue and surgical schedules fast. Tight inventory control also helps protect sterile product quality and support hospital demand.
Marketing and Sales
STAAR Surgical Company sells EVO ICL through surgeon education, clinical evidence, and distributor ties, so marketing and sales are built around trust, not discounting. In fiscal 2025, that matters because the franchise targets premium elective vision correction, where surgeon adoption and patient confidence drive demand more than price.
The model scales by training doctors, publishing outcome data, and using local channel partners to reach markets outside the U.S. That keeps the brand tied to clinical proof and procedure quality, which supports pricing power and repeat referral flow.
Service
STAAR Surgical Company's service layer includes case support, technical help, surgeon training, and post-market surveillance. In fiscal 2025, that support matters because Visian ICL sales depend on surgeon confidence, correct use, and repeat procedures, especially as STAAR Surgical Company reported net sales of about $335.8 million. Strong service also helps collect safety data fast, so product tweaks and training can follow real outcomes.
STAAR Surgical's global lens engine: precision manufacturing to worldwide sales
STAAR Surgical Company's primary activities turn precision inputs into implantable lenses through tight sourcing, sterile manufacturing, and lot-level quality checks. In fiscal 2025, that control supported a global ICL franchise sold in over 75 countries.
Finished lenses move through controlled warehousing and distributor channels, where on-time, error-free delivery matters because fiscal 2025 net sales were about $271.9 million.
Sales and service depend on surgeon training, clinical evidence, case support, and post-market surveillance to protect trust and repeat use.
| Primary activity | FY2025 data |
|---|---|
| Operations | Sterile lens manufacturing |
| Outbound logistics | Sold in over 75 countries |
| Sales | Net sales about $271.9 million |
What You See Is What You Get
STAAR Surgical Reference Sources
This is the actual STAAR Surgical Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is taken directly from the full report, so what you see is what you get. Purchase unlocks the complete, detailed version for immediate use.
Frequently Asked Questions
STAAR Surgical Company's value chain centers on a focused implantable-lens portfolio led by Visian ICL. The product is used across 3 refractive indications-myopia, hyperopia, and astigmatism-and that narrow scope lets STAAR Surgical Company concentrate R&D, surgeon training, and manufacturing discipline around 1 core platform globally.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.